Peripheral Blood Monocyte Subset Assessment in Non–ST-Segment Elevation Myocardial Infarction Is Required  by Kavsak, Peter A. & Jaffe, Allan S.
R1
2
3
4
5
6
7
8
P
S
N
M
W
a
o
a
s
i
r
i
r
k
a
r
f
e
m
“
m
t
m
a
a
C
a
t
g
d
a
(
d
c
(
t
m
i
b
r
e
w
i
s
s
s
i
*
A
*
H
7
H
C
E
R
1
2
3
4
5
6
R
W
c
q
p
i
o
169JACC Vol. 55, No. 2, 2010 Correspondence
January 12, 2010:167–72EFERENCES
. Nieuwlaat R, Eurlings LW, Cleland JG, et al. Atrial fibrillation and
heart failure in cardiology practice: reciprocal impact and combined
management from the perspective of atrial fibrillation: results of the
Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol 2009;53:
1690–8.
. Fauchier L, Grimard C, Pierre B, et al. Comparison of beta blocker and
digoxin alone and in combination for management of patients with
atrial fibrillation and heart failure. Am J Cardiol 2009;103:248–54.
. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm
relationships with bisoprolol benefit in chronic heart failure in CIBIS II
trial. Circulation 2001;103:1428–33.
. van Veldhuisen DJ, Aass H, El Allaf D, et al., on behalf of the
MERIT-HF Study Group. Presence and development of atrial fibril-
lation in chronic heart failure. Experiences from the MERIT-HF study.
Eur J Heart Fail 2006;8:539–46.
. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006
guidelines for the management of patients with atrial fibrillation—
executive summary: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines and the
European Society of Cardiology Committee for Practice Guidelines
(Writing Committee to Revise the 2001 Guidelines for the Manage-
ment of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006;
854–906.48:
. Van Gelder IC, Van Veldhuisen DJ, Crijns HJ, et al. Rate Control
Efficacy in Permanent Atrial Fibrillation: a comparison between lenient
versus strict rate control in patients with and without heart failure.
Background, aims, and design of RACE II. Am Heart J 2006;152:
420–6.
. Majumdar SR, McAlister FA, Furberg CD. From knowledge to
practice in chronic cardiovascular disease: a long and winding road.
J Am Coll Cardiol 2004;43:1738–42.
. Graham ID, Logan J, Harrison MB, et al. Lost in knowledge transla-
tion: time for a map? J Contin Educ Health Prof 2006;26:13–24.
eripheral Blood Monocyte
ubset Assessment in
on–ST-Segment Elevation
yocardial Infarction Is Required
e read with great interest both the research paper by Tsujioka et
l. (1) and the editorial comment by Shantsila and Lip (2)
utlining the role of monocytes in myocardial infarction (MI). We
gree that understanding the role of different monocyte population
ubsets during acute coronary syndromes (ACS) might provide
mportant clinical information; however, much more work is
equired, and there is a need to express some cautionary notes. An
mportant limitation in the paper by Tsujioka et al. (1) and others
eferenced by Shantsila and Lip’s editorial (2) in considering the
inetics of monocyte chemoattractant protein (MCP)-1 release (3)
re the small sample sizes (n  36 and n  23 for MI,
espectively). Thus, interpretation must be restrained. Our data
rom 216 patients with ACS do not support the association of the
arly release kinetics of MCP-1 (the ligand for chemokine [C-C
otif] receptor 2 [CCR-2]). Thus, the idea that it is related to the
prompt up-regulation of CCR-2 expressing CD14CD16-
onocytes” might not be correct (2). In our larger ACS popula-
ion, we found no time-dependent increase in MCP-1 measure-
ent during the first 12 h after the onset of symptoms (4). In
ddition, Tsujioka et al. (1) present data indicating that there was
n increase in the CD14CD16 subgroup (these cells lack dCR-2; refer to Figs. 3B and 4D in Tsujioka et al. [1]) in that at
dmission the levels were lower in the MI group as compared with
he stable angina group, with subsequent peak levels in the MI
roup significantly higher (1). However, this cell subpopulation
id not correlate with myocardial salvage (1). Moreover, the data
re from patients with ST-segment myocardial infarction
STEMI), which tend to be larger infarctions. Data in a more
iverse group, including those with smaller events diagnosed with
ardiac troponin—which is recommended by the guidelines groups
5)—would be important to see whether differences exist between
hose groups (1).
If monocyte subgroups are important in non-STEMI, they
ight prove extremely useful in deciding on the timing of invasive
ntervention. Non-STEMI patients benefit from early intervention
ut not necessarily immediate intervention (6). Perhaps data
elated to monocyte activity and expression would help to differ-
ntiate those who might benefit immediately from those who can
ait for some hours. Such considerations will require detailed
nformation on the effects of invasive interventions on monocyte
ubgroups as well as whether serial monitoring is required for risk
tratification. These are important issues, which when addressed will
hed additional light on the role of monocytes and their laboratory use
n risk stratification for patients presenting with ACS.
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eply
e are grateful to Drs. Kavsak and Jaffe for their valuable
omments and suggestions to our study (1). They pose a
uestion regarding the kinetics of monocyte chemoattractant
rotein (MCP)-1 release. They found no time-dependent
ncrease in MCP-1 measurement during the first 12 h after the
nset of symptoms in 216 patients with acute coronary syn-
romes (2). On the contrary, Matsumori et al. (3) have
